With its Tesaro buyout, GlaxoSmithKline CEO Emma Walmsley finally beefed up in oncology, one of the fields she tagged for growth about a year ago. For the small biotech, the sale marked the end of a longer and more arduous
read moreAbbVie has been on a hot streak lately thanks to the performance of its bestselling Humira, but as the company looks to the future, it has decided to tweak its management team. The company is consolidating its executive team into four managers
read moreAmid an industrywide shift away from the sector, Bristol-Myers Squibb is close to becoming the latest Big Pharma to exit consumer health. And word is Japan’s Taisho will be the one to help the company do it. More: Bristol-Myers Squibb
read moreJohnson & Johnson is taking its baby powder case to consumers. A new print and online ad will begin running this week contending “Our talc is safe” and asking people to read the scientific evidence for themselves. More: What to
read moreNovartis is weighing an insurance method often associated with natural disasters to help win coverage for its pricey next-generation cell and gene therapies. Reinsurance would underwrite a different sort of catastrophe, Novartis CEO Vas Narasimhan told the Financial Times. More: As
read moreThe PharmaTimes Clinical Researcher of the Year – The Americas competition in association with MAGI will close for entry on the 31st January 2019 so start the entry process now to avoid running out of time! More: Make sure you
read more© 1994 - 2026 B.M. Pharmaceuticals